Amedica (NASDAQ: AMDA) is one of 19 publicly-traded companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its competitors? We will compare Amedica to similar businesses based on the strength of its risk, earnings, dividends, analyst recommendations, valuation, profitability and institutional ownership.
Insider and Institutional Ownership
62.5% of Amedica shares are owned by institutional investors. Comparatively, 54.4% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 0.1% of Amedica shares are owned by company insiders. Comparatively, 10.3% of shares of all “Medical Devices & Implants” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
This is a breakdown of recent ratings and recommmendations for Amedica and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Amedica presently has a consensus price target of $60.00, suggesting a potential upside of 1,734.86%. As a group, “Medical Devices & Implants” companies have a potential upside of 35.50%. Given Amedica’s higher possible upside, equities analysts clearly believe Amedica is more favorable than its competitors.
Valuation and Earnings
This table compares Amedica and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Amedica||$15.23 million||-$16.59 million||N/A|
|Amedica Competitors||$1.67 billion||$207.58 million||94.34|
Amedica’s competitors have higher revenue and earnings than Amedica.
This table compares Amedica and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Amedica has a beta of -2.08, meaning that its share price is 308% less volatile than the S&P 500. Comparatively, Amedica’s competitors have a beta of 0.47, meaning that their average share price is 53% less volatile than the S&P 500.
Amedica competitors beat Amedica on 8 of the 12 factors compared.
Amedica Corporation is a commercial biomaterial company. The Company is a vertically integrated silicon nitride orthopedic medical device manufacturer. It is focused on using its silicon nitride ceramic technology platform to develop, manufacture and sell a range of medical devices. It is also engaged in developing wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company markets its Valeo family of silicon nitride interbody spinal fusion devices in the United States, Europe and Brazil for use in the cervical and thoracolumbar areas of the spine. In addition to its silicon nitride-based spinal fusion products, it markets a line of non-silicon nitride spinal surgery products, which allows the Company to provide surgeons and hospitals with a solution for spinal procedures. Its Valeo interbody spinal fusion devices include Anterior Lumbar, Posterior Lumbar, Oblique Lumbar, Transforaminal Lumbar, Lateral Lumbar, Cervical and Corpectomy.
Receive News & Ratings for Amedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedica and related companies with MarketBeat.com's FREE daily email newsletter.